Ionis Pharmaceuticals, Inc. (IONS)

Over the past six months, Ionis Pharmaceuticals' stock has experienced significant positive movement, increasing by 132.39% from May 7, 2025, to May 6, 2026, and by 169.43% over the last 12 months. Key events impacting the stock price include strong first-quarter 2026 earnings, leading to a 3.73% rise in pre-market trading. The company raised its full-year 2026 revenue guidance to between $875 million and $900 million, an increase of $75 million from previous estimates. Successful launches of Tryngolza and Dawnzera have contributed significantly to revenue growth, and the company increased its annual peak sales estimate for olezarsen (Tryngolza). The company exceeded its 2025 financial guidance due to continued commercial success, primarily driven by Tryngolza product sales and higher royalty revenue.

Based on the available information, there is no explicit indication of demand seasonality for Ionis Pharmaceuticals' products and services. Demand for such treatments is typically driven by disease prevalence, diagnosis rates, and access to treatment rather than seasonal variations.

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA-targeted medicines for serious diseases, operating within the Biotechnology sector and Drug Discovery industry. The company pioneers antisense therapy, RNA interference, and CRISPR therapeutics, focusing on developing innovative medicines for unmet medical needs through its antisense technology platform. Ionis focuses on treatments for rare diseases, neurological disorders, and cardiovascular conditions. Major products include Spinraza for SMA, developed with Biogen; Tryngolza, the first FDA-approved treatment for adults with FCS; Wainua for ATTRv-PN, launched with AstraZeneca; Qalsody for ALS in adults with a SOD1 gene mutation, launched by Biogen; Tegsedi for hATTR; Waylivra, a cardiology drug; Dawnzera for HAE; and Zilganersen, an upcoming launch for Alexander disease in 2026.

Ionis Pharmaceuticals is headquartered in Carlsbad, California, and is developing a new facility in Oceanside, California, expected to be occupied in 2025 with manufacturing beginning in mid-2026. The company has expanded the commercialization of some products to Europe through partners, such as Tryngolza with Sobi.

Ionis Pharmaceuticals maintains a reputation as a pioneer and leader in RNA-targeted therapeutics, committed to discovering and delivering medicines for serious diseases. The company emphasizes its dedication to discovering novel medicines and its commitment to patients. There is no specific information indicating negative events that have significantly impacted Ionis Pharmaceuticals' brand reputation in the past year. The company's communications highlight its ongoing innovation, successful product launches, and a strong pipeline, reinforcing a positive public image.

Ionis Pharmaceuticals' ownership is primarily held by institutional investors. As of May 5, 2026, the company had 504 institutional owners and shareholders holding a total of 170,993,426 shares. Major institutional owners include Fmr Llc, Capital World Investors, Vanguard Group Inc, BlackRock, Inc., T. Rowe Price Investment Management, Inc., Wellington Management Group Llp, Bellevue Group AG, State Street Corp, Geode Capital Management, Llc, and Two Sigma Advisers, Lp.